NASDAQ:RVPH
Reviva Pharmaceuticals Holdings, Inc.
- Stock
Last Close
1.71
17/05 20:00
Market Cap
108.04M
Beta: 0.10
Volume Today
301.67K
Avg: 140.38K
PE Ratio
−2.39
PFCF: −4.77
Feb '20 | Dec '20 | Dec '21 | Dec '22 | ||
|---|---|---|---|---|---|
average inventory | |||||
average payables | 616.29K - | 758.81K 23.13% | 2.01M 165.54% | ||
average receivables | |||||
book value per share | -2.46 - | 2.43 198.71% | 1.94 20.08% | 0.63 67.46% | |
capex per share | |||||
capex to depreciation | |||||
capex to operating cash flow | |||||
capex to revenue | |||||
cash per share | 23.55 - | 2.86 87.85% | 2.01 29.85% | 0.95 52.72% | |
days of inventory on hand | |||||
days payables outstanding | 507.68 - | ||||
days sales outstanding | |||||
debt to assets | 1.45K - | ||||
debt to equity | -0.55 - | ||||
dividend yield | |||||
earnings yield | -0.03 - | -0.14 388.49% | -0.20 41.00% | -0.29 47.19% | |
enterprise value | 33.02M - | 18.00M 45.50% | 13.06M 27.45% | 64.43M 393.39% | |
enterprise value over ebitda | -87.82 - | -7.73 91.20% | -1.29 83.28% | -2.67 106.76% | |
ev to operating cash flow | -151.17 - | -4.83 96.80% | -1.22 74.66% | -3.40 177.61% | |
ev to sales | |||||
free cash flow per share | -0.08 - | -1.22 1,443.43% | -0.72 40.73% | -0.97 34.69% | |
free cash flow yield | -0.01 - | -0.14 1,764.83% | -0.25 79.26% | -0.23 8.41% | |
graham net net | 21.09 - | 2.43 88.50% | 1.82 24.84% | 0.61 66.53% | |
graham number | 4.11 - | 8.21 99.77% | 5.01 38.95% | 4.21 16.08% | |
income quality | 0.26 - | 0.98 281.75% | 1.25 27.13% | 0.78 37.77% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | |
interest coverage | -0.80 - | -1.68 108.68% | -4.19K 249,729.02% | -132.97 96.82% | |
interest debt per share | 1.53 - | 0.47 68.95% | 0.00 99.97% | 0.01 5,638.99% | |
inventory turnover | |||||
invested capital | -0.55 - | ||||
market cap | 29.26M - | 26.76M 8.54% | 42.75M 59.74% | 82.95M 94.04% | |
net current asset value | -6.81M - | 7.43M 209.01% | 28.69M 286.21% | 12.32M 57.07% | |
net debt to ebitda | -10.01 - | 3.76 137.57% | 2.94 21.89% | 0.77 73.86% | |
net income per share | -0.31 - | -1.24 304.30% | -0.58 53.37% | -1.25 116.45% | |
operating cash flow per share | -0.08 - | -1.22 1,443.43% | -0.72 40.73% | -0.97 34.69% | |
payables turnover | 0.72 - | ||||
receivables turnover | |||||
research and ddevelopement to revenue | |||||
return on tangible assets | -325.70 - | -0.43 99.87% | -0.27 37.15% | -1.29 373.97% | |
revenue per share | |||||
roe | 0.12 - | -0.51 509.60% | -0.30 41.66% | -1.98 565.22% | |
roic | 0.12 - | -0.33 364.70% | -0.35 7.54% | -1.98 460.36% | |
sales general and administrative to revenue | |||||
shareholders equity per share | -2.46 - | 2.43 198.71% | 1.94 20.08% | 0.63 67.46% | |
stock based compensation to revenue | |||||
tangible asset value | -6.81M - | 7.43M 209.07% | 28.69M 286.11% | 12.32M 57.07% | |
tangible book value per share | -2.46 - | 2.43 198.71% | 1.94 20.08% | 0.63 67.46% | |
working capital | -6.81M - | 7.43M 209.01% | 29.06M 291.23% | 12.88M 55.66% |
All numbers in USD (except ratios and percentages)